Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ontamalimab in moderate to severe ulcerative colitis
NCT01620255Phase 2Completed
- Sponsor
- Takeda
- Start
- Nov 2012
- Primary completion
- Sep 2014
- Modality
- Monoclonal Antibodies
- Countries
- 21
01
Overview
A Phase 2 trial of ontamalimab in ulcerative colitis (UC), sponsored by Takeda. Started Nov 2012; status: completed.
02
Drugs
ontamalimab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT01620255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01620255.